The company believes the pandemic will accelerate the adoption of its cancer diagnostics as patients and doctors look for faster and more convenient tests.
The seven technologies feature different methods, including CRISPR and microfluidics, and can be performed in many settings and with a variety of sample types.
According to the Wall Street Journal, the Food and Drug Administration may soon issue an Emergency Use Authorization for convalescent plasma to treat COVID-19 patients.
